التفاصيل البيبلوغرافية
| العنوان: |
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience |
| المؤلفون: |
Oliver, Kate E, Brady, William E, Birrer, Michael, Gershenson, David M, Fleming, Gini, Copeland, Larry J, Tewari, Krishnansu, Argenta, Peter A, Mannel, Robert S, Secord, Angeles Alvarez, Stephan, Jean-Marie, Mutch, David G, Stehman, Frederick B, Muggia, Franco M, Rose, Peter G, Armstrong, Deborah K, Bookman, Michael A, Burger, Robert A, Farley, John H |
| المصدر: |
Gynecologic Oncology, vol 147, iss 2 |
| بيانات النشر: |
eScholarship, University of California |
| سنة النشر: |
2017 |
| المجموعة: |
University of California: eScholarship |
| مصطلحات موضوعية: |
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Ovarian Cancer, Rare Diseases, Adenocarcinoma, Clear Cell, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Cystadenocarcinoma, Serous, Disease-Free Survival, Female, Humans, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Paclitaxel, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Survival Rate, Histology, Ovarian, Survival, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis |
| جغرافية الموضوع: |
243 - 249 |
| الوصف: |
PurposeWe examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC).MethodsWe reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous).ResultsThere were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further. In early stage (I-II) patients, PFS was significantly better in OCCC than in SOC patients. For late stage (III, IV) patients, OCCC had worse PFS and OS compared to SOC, OS HR=1.66 (1.43, 1.91; p<0.001). After adjusting for age and stratifying by protocol and treatment arm, stage, performance status, and race, OCCC had a significantly decreased OS, HR=1.53 (1.33, 1.76; p<0.001). In early stage cases, there was a significantly decreased treatment effect on PFS for consolidative therapy with weekly Paclitaxel versus observation in OCCC compared to SOC (p=0.048).ConclusionsThis is one of the largest analyses to date of OCCC treated on multiple cooperative group trials. OCCC histology is more common than SOC in early stage disease. When adjusted for prognostic factors, in early stage patients, PFS was better for OCCC than for SOC; however, in late-stage patients, OCCC was significantly associated with decreased OS. Finally, treatment effect was influenced by histology. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
unknown |
| العلاقة: |
qt01v2r25q; https://escholarship.org/uc/item/01v2r25qTest |
| الإتاحة: |
https://escholarship.org/uc/item/01v2r25qTest |
| حقوق: |
CC-BY |
| رقم الانضمام: |
edsbas.CC5F44B7 |
| قاعدة البيانات: |
BASE |
